Global Ophthalmic Lasers Market - 2024-2031

Global Ophthalmic Lasers Market - 2024-2031

Global ophthalmic lasers market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.

The term LASER is an abbreviation that stands for Light Amplification by Stimulated Emission of Radiation. The laser is a source of coherent, directional, monochromatic light that can be precisely focused into a small spot. The laser is a very useful tool for a wide variety of clinical diagnostic and therapeutic procedures.

Ophthalmic lasers are medical devices specifically designed for use in ophthalmology, the branch of medicine focused on the diagnosis and treatment of eye disorders. These lasers emit highly focused beams of light with specific wavelengths, allowing precise targeting of ocular tissues for therapeutic or surgical purposes. Ophthalmic lasers have revolutionized the field of eye care by offering minimally invasive treatment options for a wide range of ophthalmic conditions. Ophthalmic lasers offer several advantages over traditional surgical techniques, including precise tissue targeting, minimal collateral damage to surrounding tissues, shorter recovery times and reduced risk of complications.

Market Dynamics: Drivers

Rising advancements in ophthalmic lasers

The rising advancements in ophthalmic lasers are expected to drive the market over the forecast period. Advancements in ophthalmic lasers have led to the development of new treatment modalities and expanded applications across various ophthalmic conditions. Advanced ophthalmic lasers allow for greater customization and personalization of treatments based on individual patient characteristics and specific ocular conditions. This trend towards personalized medicine enhances treatment efficacy and patient outcomes, driving demand for advanced laser systems with tailored treatment capabilities.

For instance, on January 11, 2024, Iridex Corporation launched its next-generation platform Iridex 532 and Iridex 577 Lasers. Both lasers harness multiple treatment modes including continuous-wave and Iridex’ patented MicroPulse Technology and an intuitive touchscreen interface providing a wide range of clinical control options and features to optimize the treatment of retinal disorders and glaucoma.

Additionally, on July 21, 2022, MaxiVision Eye Hospital introduced Technolas Teneo 317 Model 2 (Teneo M2). The Teneo M2 is an advanced, high-performance excimer laser, designed with expert German engineering design. It provides customized treatments for a wide range of patients, correcting presbyopia, myopia and hyperopia, and astigmatism. Unique to the TENEO M2, the SUPRACOR treatment is a true varifocal LASIK for presbyopic patients looking for improved quality of vision without glasses for most daily activities.

Patients increasingly seek advanced treatment options that offer superior outcomes, minimal downtime and enhanced safety. The rising demand for minimally invasive and technologically advanced ophthalmic procedures is driving healthcare providers to invest in state-of-the-art laser systems to meet patient expectations and remain competitive in the market. Hence, the major market players are focussing on the development of ophthalmic lasers with advanced features.

For instance, on December 08, 2022, Lumibird Medical launched its next generation YAG/SLT laser, the Tango Reflex Neo, by Ellex. A fully integrated Q-switched Nd: YAG and frequency-doubled Nd: YAG laser for anterior segment YAG and glaucoma indications, Tango Reflex Neo features second-generation Reflex technology with True Coaxial Illumination (TCI), designed to enhance visualization of anterior and posterior segments. New features introduced with the fully integrated laser include Imprint, a dynamic heads-up display with a real-time view of treatment settings within the binoculars, and joystick control of energy settings. It also features up to 2 mm YAG posterior offset, facilitating PROcap – Premium Refractive Outcome Capsulotomies.

Further, the increasing prevalence of various ophthalmic disorders, rising adoption of minimally invasive procedures, growing aging population, rising demand for vision correction, rising awareness and increasing technological advancements in the ophthalmic lasers are the factors expected to drive the market over the forecast period.

Restraints

Factors such as high costs associated with ophthalmic lasers, competition from alternative ophthalmic devices, risk of developing laser eye surgery side-effects and unmet needs associated with ophthalmic laser surgery are the factors expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global ophthalmic lasers market is segmented based on product type, application, end-user and region.

The photo disruptive lasers segment accounted for approximately 37.5% of the ophthalmic lasers market share

The photo disruptive lasers especially the Nd: YAG lasers segment is expected to hold the largest market share over the forecast period. Nd: YAG lasers emit light at a wavelength of 1064 nanometers, which is well-absorbed by pigmented tissues like the iris and the retina. This allows for precise tissue disruption without causing damage to surrounding structures. In ophthalmology, Nd: YAG lasers are commonly used for iridotomy and posterior capsulotomy after cataract surgery to improve visual acuity by clearing the line of sight.

For instance, on April 19, 2022, Lumibird Medical launched its new Capsulo Nd: YAG laser platform, designed for efficient and accurate capsulotomy and iridotomy treatments. Advanced illumination with a variable-height light tower offers dual illumination angles of 16 and 7.5° for anterior and posterior laser applications. The Capsulo Nd: YAG laser can be paired with the Quantel Medical Vitra 2 MultiSpot photocoagulating laser, also from Lumibird Medical, combining pan-retinal photocoagulation functionality through a single slit lamp.

Nd: YAG lasers have versatile applications in ophthalmology. They can also be used for peripheral iridotomy, treatment of secondary glaucoma caused by pupillary block, and in certain cases of retinal detachment where peripheral retinal holes need to be created to relieve traction. Nd: YAG laser procedures are typically quick, often taking just a few minutes to complete. This allows for efficient use of clinical resources and patient throughput. Thus, the market players expanding this laser segment.

For instance, on January 25, 2024, Meridian Medical launched its line of ophthalmic lasers in the US. Meridian received FDA approval for the MR Q family of lasers. The lasers include MR Q, a fully integrated ND: YAG laser combined with a precision optics LED slit lamp with a magnification range from 6 × up to 40 × selectable in 5 fixed steps. MR Q SLT, an Nd: YAG laser combined with a selective laser trabeculoplasty (SLT) photo-regenerator. MR Q supine, an Nd: YAG laser designed to treat patients in the supine position, featuring ergonomic 0–210° tiltable Haag-Streit binoculars to improve the surgeons’ comfort and visual quality.

The FDA approval of the MR Q line comes after Meridian received FDA approval for the Merilas line of lasers, including the Merilas 532 alpha green laser photocoagulator, Merilas 532 short pulse single spot laser, Merilas 577 short pulse yellow laser photocoagulator, and Merilas 810 short pulse diode laser therapy for glaucoma and retina treatment.

Geographical Analysis

North America accounted for approximately 42.4% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and rising FDA approvals. North America especially the United States is a home for its strong presence of major market players such as medical device companies. This presence of major players in the region expanding the market by developing advanced ophthalmic lasers to improve visual outcomes and enable fast visual recovery, following by the FDA approvals, which is also expected to drive the market in the region.

For instance, on April 27, 2023, Johnson & Johnson Vision cleared that its new ELITA Femtosecond Laser has received FDA 510(k) clearance for the creation of LASIK flaps. ELITA Femtosecond Laser offers a generational leap in corneal refractive technology, with benefits for surgeons, practices and patients alike. The ELITA Femtosecond laser flap innovation delivers exceptional ease and efficiency for practices, with an intuitive user interface, modular design and a quick system startup in less than 5 minutes and also delivers better outcomes for patients, with features designed to reduce complications, improve visual outcomes and enable fast visual recovery.

Additionally, on October 28, 2020, Norlase cleared the 510(k) clearance from the U.S. Food and Drug Administration and the immediate commercial launch of Norlase LION, a green laser photocoagulator fully integrated into a Keeler indirect ophthalmoscope. Unlike other laser indirect ophthalmoscopes requiring a fiber optic connection to a laser source, LION has no fiber tether, is powered by a battery and utilizes an advanced wireless interface with voice control parameters. With the new LION, ophthalmologists can experience an untethered, lightweight and portable laser treatment solution in practically any setting.

Competitive Landscape

The major global players in the ophthalmic lasers market include Lumenis Be Ltd., Alcon Inc., ZEISS Group, IRIDEX Corporation, Ellex Medical, A.R.C. Laser GmbH, Topcon Corporation, Optotek d. o. o., INTERmedic Arfran and NIDEK CO., LTD. among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global ophthalmic lasers market. During the coronavirus disease 2019 (COVID-19) pandemic, because of close contact requirements in examination and treatment techniques, the risk of infection exposure is a serious challenge in ophthalmic practice. In addition, a considerable percentage of patients presented in ophthalmology clinics belong to high-risk groups who are prone to infection. Furthermore, COVID-19 can present with only eye symptoms such as conjunctivitis without other suggestive symptoms in the early course of the disease, which might increase the possibility of infection transmission in the ophthalmology setting. This reduced the demand for ophthalmic lasers.

Market Segmentation

By Product Type
• Photo Disruptive Laser
Nd: YAG Lasers
Femto-Lasers
• Photocoagulative Laser
Argon Lasers
Diode Lasers
Double Frequency Nd: YAG Lasers
• Photo Ablative Laser (Excimer Lasers)
Xenon Chloride Lasers
Xenon Fluoride Lasers
Argon Fluoride Lasers
Argon Fluoride Lasers

By Application
• Refractive Surgery
• Cataract Surgery
• Glaucoma
• Diabetic Retinopathy
• Others

By End-User
• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers
• Specialty Eye Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Why Purchase the Report??
• To visualize the global ophthalmic lasers market segmentation based on product type, application, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of ophthalmic lasers market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global ophthalmic lasers market report would provide approximately 69 tables, 72 figures, and 187 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies